Copyright © 2000 by the European Society of Cardiology.
Catheter ablation of atrial flutter due to amiodarone therapy for paroxysmal atrial fibrillation
Medizinische Klinik I, Klinikum Großhadern, Universität München
revised July 9, 1999; accepted July 22, 1999
Abstract
Aims Antiarrhythmic drug treatment for atrial fibrillation can cause atrial flutter-like arrhythmias. The aim of this study was to clarify the effect of catheter ablation of the tricuspid annulus-vena cava inferior isthmus on amiodarone-induced atrial flutter and to determine the incidence of atrial fibrillation after catheter ablation of amiodarone-induced atrial flutter in comparison to regular typical flutter.
Methods and Results Among 92 consecutive patients with typical atrial flutter who underwent isthmus ablation 28 patients had atrial flutter without a history of previous atrial fibrillation (group I), 10 patients had atrial flutter following the initiation of amiodarone therapy for paroxysmal atrial fibrillation (group II) and 54 patients had atrial flutter and atrial fibrillation (group III). Atrial cycle length during atrial flutter in amiodarone-treated patients (group II) (277±24ms) was significantly longer as compared to the cycle length of atrial flutter in group I (247±33ms) and group III patients (235±28ms). The rate of successful transient entrainment and overdrive stimulation to sinus rhythm was not different between patients with (60%) or without amiodarone therapy (group I: 71%, group III: 53%). Successful isthmus ablation with bidirectional conduction block eliminating right atrial flutter was achieved in 90% of amiodarone-treated patients and 93% of patients without amiodarone therapy. In the amiodarone-treated patient group atrial conduction times during pacing in sinus rhythm were significantly prolonged by 20–30% before and after ablation in all regions of the reentrant circuit. During a mean follow-up of 8±3 months post-ablation, atrial fibrillation recurred in two of 10 patients on continued amiodarone therapy after successful isthmus ablation. Thus, successful catheter ablation of atrial flutter due to amiodarone therapy was associated with a markedly lower recurrence rate of paroxysmal atrial fibrillation (20%) as compared to patients with atrial flutter plus preexisting paroxysmal atrial fibrillation (76%) and was similar to the outcome of patients with successful atrial flutter ablation without preexisting atrial fibrillation (25%).
Conclusion These data suggest that isthmus ablation with bidirectional block and continuation of amiodarone therapy is an effective therapy for the treatment of atrial flutter due to amiodarone therapy for paroxysmal atrial fibrillation.
Key Words: Atrial flutter, amiodarone, catheter ablation, atrial fibrillation
f1 Correspondence: Dr C. Reithmann, Medizinische Klinik I, Klinikum Großhadern, Universität München, Marchioninistr. 15, D-81377 München, Germany.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  W Anne, R Willems, N Van der Merwe, F Van de Werf, H Ector, and H Heidbuchel Atrial fibrillation after radiofrequency ablation of atrial flutter: preventive effect of angiotensin converting enzyme inhibitors, angiotensin II receptor blockers, and diuretics Heart, September 1, 2004; 90(9): 1025 - 1030. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E Bertaglia, F Zoppo, A Bonso, A Proclemer, R Verlato, L Coro, R Mantovan, D D'Este, F Zerbo, and P Pascotto Long term follow up of radiofrequency catheter ablation of atrial flutter: clinical course and predictors of atrial fibrillation occurrence Heart, January 1, 2004; 90(1): 59 - 63. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O. Wazni, N. F. Marrouche, D. O. Martin, A. M. Gillinov, W. Saliba, E. Saad, A. Klein, M. Bhargava, D. Bash, R. Schweikert, et al. Randomized Study Comparing Combined Pulmonary Vein-Left Atrial Junction Disconnection and Cavotricuspid Isthmus Ablation Versus Pulmonary Vein-Left Atrial Junction Disconnection Alone in Patients Presenting With Typical Atrial Flutter and Atrial Fibrillation Circulation, November 18, 2003; 108(20): 2479 - 2483. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Committee Members, C. Blomstrom-Lundqvist, M. M. Scheinman, E. M. Aliot, J. S. Alpert, H. Calkins, A. J. Camm, W. B. Campbell, D. E. Haines, K. H. Kuck, et al. ACC/AHA/ESC guidelines for the management of patients with supraventricular arrhythmias --executive summary: a report of the American college of cardiology/American heart association task force on practice guidelines and the European society of cardiology committee for practice guidelines (writing committee to develop guidelines for the management of patients with supraventricular arrhythmias) Developed in Collaboration with NASPE-Heart Rhythm Society J. Am. Coll. Cardiol., October 15, 2003; 42(8): 1493 - 1531. [Full Text] [PDF]
|
|
|
|
|
|
C. Blomstrom-Lundqvist, M. M. Scheinman, E. M. Aliot, J. S. Alpert, H. Calkins, A. J. Camm, W. B. Campbell, D. E. Haines, K. H. Kuck, B. B. Lerman, et al. ACC/AHA/ESC Guidelines for the Management of Patients With Supraventricular Arrhythmias*--Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Supraventricular Arrhythmias) Circulation, October 14, 2003; 108(15): 1871 - 1909. [Full Text] [PDF]
|
|
|
|
 |
|
 Committee Members, C. Blomstrom-Lundqvist, M. M Scheinman, E. M Aliot, J. S Alpert, H. Calkins, A.J. Camm, W.B. Campbell, D. E Haines, K. H Kuck, et al. ACC/AHA/ESC guidelines for the management of patients with supraventricular arrhythmias--executive summary: A Report of the American College of Cardiology/American HeartAssociation Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines(Writing Committee to Develop Guidelines for the Management of Patients With Supraventricular Arrhythmias)Developed in collaboration with NASPE-Heart Rhythm Society Eur. Heart J., October 2, 2003; 24(20): 1857 - 1897. [Full Text] [PDF]
|
|
|
|
|
|
C. Reithmann, U. Dorwarth, M. Dugas, A. Hahnefeld, S. Ramamurthy, T. Remp, G. Steinbeck, and E. Hoffmann Risk factors for recurrence of atrial fibrillation in patients undergoing hybrid therapy for antiarrhythmic drug-induced atrial flutter Eur. Heart J., July 1, 2003; 24(13): 1264 - 1272. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Capucci, G.Q. Villani, N. Marrazzo, and M. Piepoli The complementary role of drug, ablation and device in the electrical therapy of atrial fibrillation Eur. Heart J. Suppl., November 1, 2001; 3(suppl_P): P47 - P52. [Abstract] [PDF]
|
|
|
|
|
|
D. Katritsis Cavotricuspid isthmus ablation and atrial fibrillation Eur. Heart J., December 2, 2000; 21(24): 2080 - 2080. [PDF]
|
|
|
|
|
|
P. Geelen and P. Brugada Hybrid theraphy for atrial fibrillation Eur. Heart J., April 1, 2000; 21(7): 509 - 510. [PDF]
|
|